Palvella Therapeutics (PVLA) director awarded 3,000 stock options at $102.19
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share. These options expire on June 10, 2036 and vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KIRITSY CHRISTOPHER P
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option shares granted: 3,000 shares
Exercise price: $102.19 per share
Underlying shares: 3,000 shares
+3 more
6 metrics
Option shares granted
3,000 shares
Stock Option (Right to Buy) grant to director
Exercise price
$102.19 per share
Conversion/exercise price of stock options
Underlying shares
3,000 shares
Common stock underlying the options
Post-grant option holdings
3,000 options
Total options held after transaction
Expiration date
June 10, 2036
Option term end date
Vesting condition
Earlier of 1-year or next annual meeting
Subject to continued service through vesting date
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 102.1900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders following the grant date"
FAQ
What did Palvella Therapeutics (PVLA) director Christopher P. Kiritsy report on this Form 4?
Christopher P. Kiritsy reported receiving a grant of stock options for 3,000 shares of Palvella Therapeutics common stock. The filing reflects a compensation-related award rather than an open-market stock purchase or sale.
What is the exercise price of Christopher P. Kiritsy’s Palvella (PVLA) stock options?
The options have an exercise price of $102.19 per share. This is the price Kiritsy would pay to purchase each underlying share if he exercises the stock options in the future.
When do Christopher P. Kiritsy’s Palvella Therapeutics (PVLA) stock options vest?
The options vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Kiritsy’s continued service through the applicable vesting date.
When do the newly granted Palvella (PVLA) stock options expire?
The stock options granted to Christopher P. Kiritsy expire on June 10, 2036. After that expiration date, any unexercised options will no longer be exercisable for Palvella Therapeutics common stock.
How many Palvella (PVLA) options does Christopher P. Kiritsy hold after this grant?
Following this grant, Kiritsy holds 3,000 stock options according to the filing. These options relate to an equal number of underlying shares of Palvella Therapeutics common stock.